.png){kind=icon}
.png){kind=icon}
Return
Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real-World National Study
.png){kind=icon}
OA
AI
E
P
C
M
H
T
N
D
S
C
O
R
C
C
C
C
DOI：10.1111/dom.71169.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real-world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Keywords:
diabetic nephropathy
insulin secretion
observational study
SGLT2 inhibitor
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
D
IF:
5.7
Papers:
372
Citations:
0
Organization
Cited Papers